on Heidelberg Pharma AG (ETR:HPHA)
Heidelberg Pharma's Promising Mid-Year 2025 Developments
Heidelberg Pharma AG announced noteworthy progress in 2025, particularly in clinical trials and financial stability. The lead ATAC candidate, HDP-101, showed promising results in multiple myeloma trials, reaching the eighth cohort with positive tolerance and efficacy results. Additionally, the first patient was dosed with HDP-102 for non-Hodgkin lymphoma.
The company amended its contract with HealthCare Royalty, securing a USD 20 million payment, with USD 70 million anticipated after TLX250-CDx approval. The upcoming financial forecast projects funding stability through 2027. Despite experiencing a net loss increase to EUR 12.6 million, the company's strategic actions ensure continued research and operational momentum.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Heidelberg Pharma AG news